TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06770374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group: silicone adhesive sutureless fixation device
Description: The standard care consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and silicone adhesive sutureless fixation device (3300MWA Grip-Lok®).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Group: zinc oxide sutureless fixation device
Description: Alternative care consisted of:~* Application of haemostasis at the insertion site for 2 minutes post-puncture or until cessation of bleeding.~* Fixation with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and zinc oxide sutureless fixation device (2200NUZA Grip-Lok®).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC
Description: The PICC lines used in the study will all be third-generation polyurethane and of the commercial brands:~* PowerPICC™ 4, 5 and 6 Fr from BD~* Maxflo expert™ 5 and 6 Fr from Vygon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICC
Description: The PICC lines used in the study will all be third-generation polyurethane and of the commercial brands:~* PowerPICC™ 4, 5 and 6 Fr from BD~* Maxflo expert™ 5 and 6 Fr from Vygon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline
Description: The midline lines used in the study will be second or third generation polyurethane and of the commercial brands:~* PowerMidline™ 4 Fr from BD~* Arrow® Midline 4Fr from Arrow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline
Description: The midline lines used in the study will be second or third generation polyurethane and of the commercial brands:~* PowerMidline™ 4 Fr from BD~* Arrow® Midline 4Fr from Arrow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound scanner
Description: All punctures will be performed under ultrasound guidance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scanner
Description: All punctures will be performed under ultrasound guidance.
Study: NCT06772116

Intervention type: PROCEDURE
Intervention: Focal Therapy
Description: Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).~Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed.
Study: NCT06773104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant and grafting with autogenous tooth bone graft
Description: In autogenous tooth bone graft group:~Any restorations, caries, cementum, periodontal ligament and pulp tissue will be removed .The tooth will be grinded using dental bone mill and bone crusher Tooth particles will be sieved to particles size 300 to 1200 microns. The sorted particles will be immersed in 70 % ethanol and 5% Peracetic acid\* in a sterile container for 10 minutes to remove any soft tissue remnants, bacteria and smear layer (defatting and sterilization).~Tooth particles will be demineralized using 2% HNO3‡ for 20 minutes to expose the dentine organic matrix.~The bacteria-free particulate dentin will be washed with phosphate buffered saline‡ twice for 5 minutes to restore the PH balance to 7.4. In the same setting, after atraumatic extraction immediate implant will be inserted with graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant with allogenic bone graft
Description: after atraumatic extraction immediate implant will be inserted with allogenic bone graft
Study: NCT06774118

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05796986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular procedure of treatment of wide neck saccular cerebral aneurysm
Description: Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
Study: NCT06774625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001 High Dose
Description: LTG-001 High Dose
Study: NCT06159075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
Study: NCT05891067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SterkWerk
Description: Classroom-based intervention program
Study: NCT06774625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001 Mid Dose
Description: LTG-001 Mid Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001 Low Dose
Description: LTG-001 Low Dose
Study: NCT05891067

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Active control group
Study: NCT06774625

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001
Description: LTG-001 is a Novel, Orally Bioavailable, Small Molecule NaV1.8 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001
Description: LTG-001 is a Novel, Orally Bioavailable, Small Molecule NaV1.8 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001
Description: LTG-001 is a Novel, Orally Bioavailable, Small Molecule NaV1.8 Inhibitor
Study: NCT06771323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: To assess if valbenazine 80mg daily improves motor symptoms in idiopathic CD patients with persistent symptoms despite current treated with botulinum toxin injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: To assess if valbenazine 80mg daily improves motor symptoms in idiopathic CD patients with persistent symptoms despite current treated with botulinum toxin injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06770621

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia test
Description: For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon profile
Description: The subject must fast before the consultation and follow a specific diet the day before; after an initial blood draw (P1), the patient will have breakfast and take any required insulin, followed by two additional blood draws 1.5 hours after breakfast (P2) and 1.5 hours after P2 (P3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample once
Description: The exome of each patient will then be analyzed from the blood sample taken beforehand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation-questionnaire
Description: only the answer to a questionnaire
Study: NCT06770764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODC-IL2
Description: ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODC-IL2
Description: ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.
Study: NCT06772090

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus and Bifidobacterium
Description: Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61\>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62\>).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule manufactured in same facility as experimental capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule manufactured in same facility as experimental capsule.
Study: NCT06775028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iABC platform use
Description: The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
Study: NCT06768333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams Voom Pocket Rocket Electro Energy
Description: Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams Maurten Gel 160
Description: Participants will be required to consume 45 grams (in carbohydrates) of the Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 45 grams SIS Go Isotonic Energy Gel
Description: Participants will be required to consume 45 grams (in carbohydrates) of the SIS Go Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
Study: NCT06774417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital nudge
Description: Digital help seeking advancement strategies over text and online.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital nudge
Description: Digital help seeking advancement strategies over text and online.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital nudge
Description: Digital help seeking advancement strategies over text and online.
Study: NCT06774885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 1 Mg Oral Tablet
Description: 1 mg oral folic acid tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid 5 Mg Oral Tablet
Description: 5 mg oral folic acid tablet
Study: NCT06154577

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
Study: NCT04693351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
Study: NCT06334588

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Anatomical and functional images will be acquired and review by an experienced neuro-radiologist

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Anatomical and functional images will be acquired and review by an experienced neuro-radiologist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Scales
Description: CGI, E-CAR and ABC will be used for behavior and clinical evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Scales
Description: CGI, E-CAR and ABC will be used for behavior and clinical evaluation

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Research of genetic anomalies
Description: For the diagnosis of autism, patients benefit from a a genetic assessment. This is carried out as part of their care
Study: NCT04884789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COFIS 3D
Description: Patient have to wear the COFIS 3D 20h a day for at least 6 month
Study: NCT06296121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-264
Description: IV, 16 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darzalex
Description: IV, 16 mg/kg
Study: NCT06484894

Intervention type: DEVICE
Intervention: Pentacam and IOL master
Description: Device used for measurement of central corneal thickness

Intervention type: DEVICE
Intervention: Pentacam and IOL master
Description: Device used for measurement of central corneal thickness

Intervention type: DEVICE
Intervention: Pentacam and IOL master
Description: Device used for measurement of central corneal thickness
Study: NCT04839861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier Family Games
Description: Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mightier online gameplay
Description: Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier online gameplay
Description: Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own.
Study: NCT04931836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
Study: NCT04693351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
Study: NCT06525077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218
Description: Sodium oxybate for extended-release oral suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo equivalent for oral suspension
Study: NCT04922307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sparing Protocol
Description: Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Replacement
Description: Allogenic blood transfusion as determined intra-operatively
Study: NCT06346379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
Study: NCT05673148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Undergo SABR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: undergo microwave ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive SOC chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Receive SOC chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT06491368

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
Study: NCT05673148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan